Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790777 | 1.00 | BRD4 (0.40) | BRD4CREBBPGABRA1GABRB2HRH1 | |
| SCHEMBL6791321 | 0.92 | HRH1 (0.42) | BRD4CREBBPGABRA1HRH1GABRG2 | |
| SCHEMBL6791319 | 0.92 | HRH1 (0.42) | BRD4CREBBPGABRA1HRH1GABRG2 | |
| SCHEMBL6782255 | 0.86 | PLAT (0.39) | LMNATSHRHTR1AHTR7CHRM1 | |
| SCHEMBL6790499 | 0.86 | HTR2C (0.41) | GABRA1GABRB2LMNATSHRHTR1A | |
| SCHEMBL6782257 | 0.86 | PLAT (0.39) | LMNATSHRHTR1AHTR7CHRM1 | |
| SCHEMBL6790502 | 0.86 | HTR2C (0.41) | GABRA1GABRB2LMNATSHRHTR1A | |
| SCHEMBL6784662 | 0.86 | ALOX5AP (0.37) | CREBBPHRH1LMNATSHRHTR1A | |
| SCHEMBL6784658 | 0.86 | ALOX5AP (0.37) | CREBBPHRH1LMNATSHRHTR1A | |
| Hydrochloric Acid SCHEMBL6781502 | 0.85 | CHRM1 (0.46) | GABRA1GABRG2GABRB3CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | disclosed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | BRD4 1644/4885CREBBP 3464/4885GABRA1 571/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | BRD4 1644/4885CREBBP 3464/4885GABRA1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.